Stockscreener 앱 받기
1.13
5.61%
0.06
시장 영업 전:
1.06
-0.07
-6.19%
전일 마감가:
$1.07
열려 있는:
$1.07
하루 거래량:
308.30K
Relative Volume:
0.35
시가총액:
$93.49M
수익:
-
순이익/손실:
$-13.73M
주가수익비율:
-8.6923
EPS:
-0.13
순현금흐름:
$-3.92M
1주 성능:
+41.23%
1개월 성능:
+1.80%
6개월 성능:
+30.65%
1년 성능:
+69.67%
1일 변동 폭
$1.01
$1.135
1주일 범위
$0.7601
$1.135
52주 변동 폭
$0.5437
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.13 | 93.49M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2018-12-17 | 개시 | Laidlaw | Buy |
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Multiple sclerosis Pipeline Analysis and Clinical Trials - openPR.com
TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan
Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive financial news
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times
Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive financial news
Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors
Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times
Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan
Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com
Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK
Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times
Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM
Tiziana Life Sciences Dodges Delisting: How Company Saved Its Nasdaq Status - Stock Titan
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it
Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews
Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com
Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha
Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com
Tiziana submits FDA investigational new drug application - Proactive Investors UK
Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com
Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks
Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times
Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Tiziana stock jumps 12% on TBI drug study publication - MSN
Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals - Proactive Investors UK
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury - The Manila Times
Can Tiziana's Nasal Therapy Revolutionize Traumatic Brain Injury Treatment? New Study Says Yes - StockTitan
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive… - Informazione.it
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive financial news
Tiziana Life Sciences nearing completion of long COVID study on foralumab - Proactive Investors UK
Tiziana Life Sciences Ltd (TLSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):